Back to all assets

Gilead Sciences GILD

equity

Price History

$0.242$49.81$99.38$148.95
1992-01 · DCA start$0.648

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-62.7%-41.8%-20.9%0.0%
1992-012026-08 · -8.8%

Worst drawdown: −63%, peaking Jan 1992 and bottoming May 1994 — 43 months below the prior high before recovering.

DCA Backtest

Invested
$41,600
Value today
$2,517,116
Return
+5950.8%
Months invested
416

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $67,451 today, so the real (inflation-adjusted) return is +3631.8%.

Lump sum instead — $41,600 all at once in Jan 1992: $8,716,627 (+20853.4%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Feb 2026): $705.51 on $700 invested (+0.8%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1992-01: +5950.8%

About Gilead Sciences

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. (Wikipedia)

It's a listed company categorised under health care and biotechnology, with a market cap of about $168.5B.

It rates High Risk at 3.1/5, meaning several rated factors score badly, so this carries materially more risk than a typical holding.

What pushes the score up: earnings quality (5.0/5) and leverage / financial (4.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

High Risk(3.1/5)80% rated

How these ratings work

Market / Volatility2.3/5 · weight 20%
  • Annualised volatility (3yr)2/520.7
  • Max drawdown from ATH3/562.7
  • Beta vs S&P 5002/50.71
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5980.4m
  • Float % of shares outstandingnot yet researched
Leverage / Financial4.0/5 · weight 20%
  • Debt / equity4/52.4
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality5.0/5 · weight 15%
  • 3yr EPS volatility5/51,256
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.